3rd Quarter - Report

W STRATEGIES, LLC for MEDIMMUNE, LLC

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

P.L. 112-144, The Food and Drug Administration Safety and Innovation Act of 2012, particularly with respect to provisions relating to drug shortages, supply chain integrity and pharmaceutical incentives for children.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.